A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects
NCT05974969
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
146
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
DRUG:
BCD-264
DRUG:
Darzalex
Sponsor
Biocad